SCHEMBL5714503

SCHEMBL5714503

CC1(C)CC(=O)N(CCc2ccc(OC(=O)N3CCN(CCCc4ccccn4)CC3)cc2)C(=O)C1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.46
HTR1A P08908 1/20 0.46
DRD2 P14416 1/20 0.46
SIGMAR1 Q99720 2/20 0.44
ADORA3 P0DMS8 1/20 0.44
HTR7 P34969 1/20 0.44
OPRM1 P35372 1/20 0.44
TP53 P04637 2/20 0.44
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.41
FAAH O00519 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714665 0.95 TP53 (0.49) HTR2AHTR1ADRD2TP53KDM4E
SCHEMBL5714929 0.92 KDM4E (0.51) KDM4EALDH1A1
SCHEMBL5714839 0.91 HTR2A (0.43) HTR2AHTR1ADRD2SIGMAR1ADORA3
SCHEMBL5715394 0.87 HTR2A (0.40) HTR2AHTR1ADRD2SIGMAR1ADORA3
SCHEMBL5715173 0.87 FAAH (0.40) HTR2AHTR1ADRD2SIGMAR1ADORA3
SCHEMBL5714754 0.86 DRD2 (0.41) HTR2AHTR1ADRD2SIGMAR1ADORA3
SCHEMBL5714515 0.85 TP53 (0.43) HTR2AHTR1ADRD2TP53KDM4E
SCHEMBL5714375 0.84 KDM4E (0.46) HTR2AHTR1ADRD2SIGMAR1ADORA3
SCHEMBL5714651 0.84 HSD17B10 (0.52) KDM4EALDH1A1LMNA
SCHEMBL5714637 0.83 ALDH1A1 (0.48) HTR2AHTR1ADRD2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL HTR2A 1618/4885HTR1A 2790/4885DRD2 3721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.